| Fagiuoli, Stefano |
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease |
|
|
| Not yet recruiting | 2 | 393 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Liver Diseases, Alcoholic | 12/26 | 03/27 | | |
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) |
|
|
| Recruiting | 2 | 280 | Europe, Canada, Japan, US, RoW | Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo | GlaxoSmithKline | Chronic Hepatitis B Virus Infection, Hepatitis B | 10/27 | 10/27 | | |
NCT05276297 / 2021-003567-10: A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy |
|
|
| Active, not recruiting | 2 | 184 | Europe, RoW | GSK3228836, Bepirovirsen, GSK3528869A, Control | GlaxoSmithKline, GlaxoSmithKline Biologicals | Hepatitis B, Chronic | 02/26 | 02/26 | | |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
| Completed | N/A | 515 | Europe | | University of Turin, Italy, Gilead Sciences | Chronic Hepatitis D | 06/24 | 12/24 | | |
| Recruiting | N/A | 250 | Europe | | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | Liver Transplant | 02/34 | 02/34 | | |
NCT05618145: National Database on Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | N/A | 6000 | Europe | Clinical information | University of Milano Bicocca | Primary Sclerosing Cholangitis | 10/32 | 10/32 | | |
| Magini, Giulia |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
| Caraceni, Paolo |
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease |
|
|
| Not yet recruiting | 2 | 393 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Liver Diseases, Alcoholic | 12/26 | 03/27 | | |
COMBAT, NCT05895136: A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome ( Trial). |
|
|
| Recruiting | 2 | 90 | Europe | Human albumin, Enoxaparin, Standard medical treatment | European Foundation for Study of Chronic Liver Failure | Liver Cirrhosis | 03/25 | 03/25 | | |
ARTE, NCT06806579: Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 1000 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Hepatocellular Carcinoma (HCC) | 10/30 | 10/31 | | |
| Completed | N/A | 1456 | Europe, US, RoW | Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy | Azienda Ospedaliera di Padova | Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome | 09/23 | 11/23 | | |
